Reviewers Over 50 Swear By These 22 Hair Care Products
A splurge-worthy Sol de Janeiro hair and body mist — seems like everyone wants to get their hands on it. It comes in the same vanilla and caramel scent as the beloved Bum Bum Cream and might just have people telling you, "Ooooh, you smell so good!"
An air-dry leave-in curl cream made to enhance your natural curls and tame frizz. No need to damage your hair with hot styling tools, this blend of coconut oil and shea butter nourishes your locks and makes them smell great too!
An anti-humidity spray to give you that salon "wow" feeling at home, and for way cheaper. This fights off frizz and leaves you with silky-looking hair. FYI, this spray is heat activated, so it's ideal to use this on damp hair and blow-dry for best results.
A dandruff shampoo so you can finally get rid of those itchy, dry flakes once and for all. This is made with 1% ketoconazole, which gets to the ~root~ of the dandruff and makes sure that your scalp will look nice and clear.
A dry shampoo powder if your hair has been looking like it's been a while since wash day. Tap this on to say goodbye to greasy roots and make it look like your hair got a nice lil' refresh. Plus, this is TSA friendly, which makes it great for traveling.
K18 — it does a stellar job at restoring moisture and softness to hair that has been through a lot, whether it's from bleaching or just frequent hot tool use. Many reviewers say this leave-in reparative treatment is like "magic in a bottle!"
Or a budget-friendly collagen-coating hair treatment with collagen and ceramide 3 to treat hair that's been through intense heat or sun damage. Use this in between your shampoo and conditioner and leave it in for five minutes — soon enough, you'll have silky soft hair!
And a splurge-worthy bottle of Olaplex No. 3 that's totally worthy of all the hype since it'll help repair and strengthen your dry, damaged hair. After using this, you'll be telling all your friends, "Feel how soft my hair is!"
A detangling brush to help make dealing with knots and tangles a less painful part of your hair care routine. The flexible bristles glide through your hair and make sure there's no yanking, pulling, or tears.
A bottle of Fanola purple shampoo if your "bleach and tone" is looking yellow and brassy. This will help neutralize your color and bring back your blonde or gray locks.
A Chi automatic curling iron for those who are tired of putting so much effort into curling their hair or those who always find a way to accidentally burn their fingers on the hot barrel. This will automatically curl your hair, and the outer casing protects your fingers from any potential ouches!
Or a set of flexible curling rods that prove you don't always need a hot tool to give you the results you've been wishing for. You just wrap your hair around these soft rods, go to bed (they're comfortable enough to sleep in), and wake up with stunning curls!
An argan oil hair mask to give your hair that hair commercial-worthy shine and moisture you've been wanting. Your dry hair and split ends will thank you for buying this since its paraben- and sulfate-free formula will make your locks look oh-so-luscious.
A Mielle rosemary mint scalp oil that contains biotin and jojoba oil, which can help nourish your scalp and make hair look fuller and thicker. It's got over 74,000 5-star reviews, and people love how it smells, too!
A curl-activating cream to help reduce breakage and frizz for all you curly-haired folks. Whether you use this at night before bed or to style your mane in the morning, you'll see bouncy, defined curls like never before, thanks to the blend of vitamins and shea butter that nourishes and detangles.
A Revlon hot air brush because the Dyson Airwrap costs an arm and a leg and this round brush gives you the same, if not better, bouncy blowout results. This dries *and* styles at the same time, saving you some extra time in the morning!
Or a 3-in-1 hot tool that's got interchangeable heads so you can choose how much va-va-va-voom you want when blow-drying and styling your hair.
A scalp massager you can use in the shower to help exfoliate your head and make sure all that shampoo really gets into those roots.
A Verb hair oil because the only ghost here is the ghost of the person you were when you had frizzy hair and constant flyaways. This moringa-infused oil tames frizz, and reviewers with hair textures from straight to 4c love this because it makes their hair look shinier and feel softer.
A hair repair serum with argan oil, aloe vera, and vitamin E to make your hair shine like the star you are while keeping the frizz at bay. Reviewers love how lightweight this feels and that it doesn't leave their hair feeling super oily or greasy.
A color-depositing conditioner — great if you find yourself wanting a little color refresh when you're in between salon appointments. With every wash, your hair color will become more vibrant, and it'll save you the hassle of messing with at-home box dyes.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
10 hours ago
- Business Wire
Zai Lab Announces China National Medical Products Administration Grants Innovative Medical Device Designation for Tumor Treating Fields for Patients with Pancreatic Cancer
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the China National Medical Products Administration (NMPA) has granted Innovative Medical Device Designation for Tumor Treating Fields (TTFields) for patients with pancreatic cancer based on the positive results from the Phase 3 PANOVA-3 trial. The Innovative Medical Device Designation allows Zai Lab to take advantage of an expedited approval procedure for TTFields that offers opportunities for the NMPA to prioritize the allocation of review resources to expedite the regulatory review and approval process. 'We are excited that TTFields has been granted the Innovative Medical Device Designation, a status that offers expedited registration and priority review by the NMPA. This designation also allows us to submit the application in China before approval in the country of origin,' said Rafael Amado, M.D., President, Head of Global Research and Development at Zai Lab. 'Pancreatic cancer remains one of the most challenging cancers to treat globally, with approximately 134,000 new cases diagnosed annually in China alone. We are on track to submit for regulatory approval in China in the second half of 2025 and look forward to collaborating closely with the NMPA throughout the review process.' The Phase 3 PANOVA-3 trial evaluated the use of TTFields therapy concomitantly with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma compared to gemcitabine and nab-paclitaxel alone. The trial met its primary endpoint, demonstrating a statistically significant improvement in median overall survival for patients treated with TTFields. Zai Lab participated in the study in Greater China (mainland China, Hong Kong, Macau and Taiwan, collectively). In August 2019, the NMPA granted Innovative Medical Device Designation for Optune ® in China for the treatment of newly diagnosed and recurrent glioblastoma (GBM). Zai Lab subsequently submitted the regulatory application in September 2019 and received approval in May 2020. Optune is a registered trademark of Novocure GmbH, and Zai Lab markets Optune under license from Novocure GmbH. About PANOVA-3 PANOVA-3 is an international prospective, randomized, open-label, controlled Phase 3 clinical trial designed to test the efficacy and safety of TTFields therapy used concomitantly with gemcitabine and nab-paclitaxel, as a first-line treatment for locally advanced pancreatic adenocarcinoma. Patients were randomized to receive either TTFields therapy concomitant with gemcitabine and nab-paclitaxel or gemcitabine and nab-paclitaxel alone. The primary endpoint is overall survival. Secondary endpoints include progression-free survival, local progression-free survival, objective response rate, one-year survival rate, quality of life, pain-free survival, puncture-free survival, resectability rate, and toxicity. The PANOVA-3 trial enrolled 571 patients who were randomized 1:1 and followed for a minimum of 18 months. About Pancreatic Cancer in China Pancreatic cancer is one of the most common and deadliest cancers globally. In China, there were an estimated 134,374 new cases and 131,203 cancer deaths in 2022, and it is the sixth leading cause of cancer mortality in China 1. Pancreatic cancer has a 5-year survival rate of less than 10%, making it the malignancy with the lowest survival rate in China 2. The patients with locally advanced, unresectable pancreatic cancer are no longer operable, so chemotherapy with or without radiation is the only treatment option, with a median overall survival only nine to twelve months. 1 Xia C, Dong X, Li H et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl) 2022; 135: 584-590. 2 Hu JX, Zhao CF, Chen WB et al. Pancreatic cancer: A review of epidemiology, trend, and risk factors. World J Gastroenterol 2021; 27: 4298-4321. About Tumor Treating Fields Tumor Treating Fields (TTFields) is a cancer therapy that uses electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. TTFields do not significantly affect healthy cells because they have different properties (including division rate, morphology, and electrical properties) than cancer cells. These multiple, distinct mechanisms work together to target and kill cancer cells. Due to these multi mechanistic actions, TTFields therapy can be added to cancer treatment modalities in approved indications and demonstrates enhanced effects across solid tumor types when used with chemotherapy, radiotherapy, immune checkpoint inhibitors, or targeted therapies in preclinical models. TTFields therapy provides clinical versatility that has the potential to help address treatment challenges across a range of solid tumors. To learn more about TTFields therapy and its multifaceted effects on cancer cells, visit About Zai Lab Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health. For additional information about Zai Lab, please visit or follow us at Zai Lab Forward-Looking Statements This press release contains forward-looking statements about future expectations, plans, and prospects for Zai Lab, including, without limitation, statements regarding the prospects of and plans for developing and commercializing TTFields therapy, the potential benefits of TTFields therapy, and the potential treatment of pancreatic cancer. These forward-looking statements may contain words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would,' and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and the SEC's website at
New York Post
a day ago
- New York Post
Is L'Oréal's Collagen Moisture Filler worth it? I tried It on dry, sensitive skin
New York Post may be compensated and/or receive an affiliate commission if you click or buy through our links. Featured pricing is subject to change. I've tried hundreds of beauty products every year, chasing that holy grail of hydration, plumpness and gentle soothing for sensitive, dry skin — and the L'Oréal Paris Collagen Moisture Filler Moisture Bounce Face Serum landed in my routine as a solid, budget-friendly option. I'm usually skeptical of anything that calls itself a 'filler' or promises to smooth wrinkles without more active anti-aging actives, but this one genuinely surprised me. Now, it's 23% off on Amazon, which is always a nice welcome when I'm restocking my skincare arsenal. I grabbed a bottle immediately, because as someone who tests a ridiculous number of products a year, I've learned that ingredient quality and sensory experience matter deeply, but so does the price-to-performance ratio. If a product delivers and is on sale? Even better. Amazon Pros: Offers deep, lasting hydration Gentle on sensitive skin Affordable price point Cons: Not 100% fragrance-free, but didn't irritate my sensitive skin The ingredients are simple yet effective. The star is soluble collagen, paired with glycerin and shea butter, and there's even frankincense extract in some versions. When used, it plumps my skin and improves its elasticity, which is especially great when you're sensitive or adverse to actives like retinol, like I tend to be. Instead of relying on boosting your own collagen, it layers moisture and improves skin tone fast, thanks to its rich base and humectant properties. That's exactly the pull for me. My skin leans dry and touches on sensitive, especially as we're nearing cold temps or when I jet lag through different climates. I needed a formula that I could use morning and night without fear of irritation, fragrance overload or greasiness. So I went in full force: cleanser, then a generous layer of this Collagen Moisture Filler. Victoria Giardina In terms of performance, I noticed that after just one week, my skin looked smoother, and after a month, those little dehydration lines (you know, the tiny crepe lines that form when you air-dry your face under a lamp) were less noticeable. L'Oréal claims that in four weeks, wrinkles appear more filled in and, though I'm not treating deep crepey aging, I can say it does give a plumper, more youthful bounce without irritation. As someone who tests hundreds of beauty products a year — everything from cutting-edge serums to cult-favorite moisturizers — I can honestly say this one stands out for its balance of gentle hydration and comfort. It's not as flashy as some of the newer peptides or acids, but it reliably moisturizes, layers well under SPF and makeup, and doesn't provoke reactions. Let me give you a typical night sequence: after cleansing and finishing any actives or serums, I pat my face until there's still a bit of moisture residue. Then I scoop a small amount of Collagen Moisture Filler and smooth it evenly across face and neck. It glides, absorbs within a minute and leaves a velvety, hydrated finish. All in all, this product reminds me why I test so many things every year — because sometimes the best finds are ones you'd glance past for lacking 'active ingredients.' For dry, sensitive skin, this collagen-rich serum works as a dependable hydrator that adds a subtle bounce with ease and comfort. And, at 23% off, it's time to pick one up. This article was written by Victoria Giardina, New York Post Commerce Journalist & Content Strategist, who has spent countless hours researching, testing hundreds of products and comparing the latest makeup, skincare, hair and beauty items and trends to determine what's truly worth your hard-earned cash. She evaluates formulas, textures, ingredients and more, in addition to consulting medical and industry experts. Some of Victoria's latest conquests include testing the best vitamin C serums on the market, and a rinse-and-repeat review of the best shampoos of 2025. Victoria, who received a beauty industry essentials certification from the Fashion Institute of Technology, has been creating shopping guides for the New York Post since 2021 and previously held positions at Insider Reviews and CNN Underscored.
Medscape
5 days ago
- Medscape
Tibremciclib for Advanced Breast Cancer: Is It Worth It?
Adding the novel CDK4/6 inhibitor tibremciclib (Betta Pharmaceuticals) to second-line fulvestrant significantly extended progression-free survival (PFS) in patients with HR-positive/HER2-negative advanced breast cancer, but with the tradeoff of increased toxicity, new data suggest. Compared with fulvestrant alone, the combination prolonged median PFS for these patients by 11 months, according to results from the phase 3 TIFFANY trial. However, similar to existing CDK4/6 inhibitors, the tibremciclib-fulvestrant combination added to treatment side effects — including substantially higher rates of diarrhea, hematologic toxicities, and hypokalemia. The authors of the analysis, published in JAMA Oncology , described the toxicities as "manageable," emphasizing that few patients stopped treatment because of them. Study author Xichun Hu, MD, of Fudan University Shanghai Cancer Center, told Medscape Medical News that tibremciclib compares favorably with other CDK4/6 inhibitors in terms of dose reduction and discontinuation rates. However, Hu noted, that's based on cross-trial comparisons, which have to be interpreted with caution. Kathy Miller, MD, who was not involved in the trial, had a similar take. 'Toxicity actually looks similar to ribociclib and palbociclib, with primarily myelosuppression and little non-heme toxicity,' Miller, of the Melvin and Bren Simon Comprehensive Cancer Center at Indiana University, told Medscape Medical News. Tibremciclib plus fulvestrant was recently approved in China for HR-positive/HER2-negative advanced breast cancer following results from the trial, but the combination has yet to be approved in the US. The Benefits vs the Risks In the trial, Hu and colleagues studied the safety and efficacy of the new agent among patients from 69 centers in China who had experienced progression while on endocrine therapy and had received no more than one line of chemotherapy. A total of 274 patients were randomized (2:1) to receive either tibremciclib (400 mg orally, once daily) or placebo plus fulvestrant until disease progression, death, or treatment discontinuation over a median follow-up of 13 months. Eighty patients (43.5%) in the tibremciclib arm and 64 (71.1%) in the placebo arm experienced a PFS event (disease progression or death). Tibremciclib plus fulvestrant significantly improved PFS to 16.5 months versus 5.6 months with fulvestrant alone, reducing the risk of progression by 63% (hazard ratio [HR], 0.37; P < .001). As for safety, adverse events were higher in the treatment arm. The most common treatment-emergent adverse events were diarrhea (79.3% in the tibremciclib arm vs 13.3% in placebo arm), neutropenia (75.5% vs 15.6%), leukopenia (73.9% vs 16.7%), and anemia (69% vs 21.1%). Nausea and vomiting were also more common with tibremciclib, at 37% and 40.2%, respectively — versus 18.9% and 11.1% in the placebo group. Most often, those adverse events were grade 1 or 2. However, 50.5% of patients in the tibremciclib group had a grade 3 or higher treatment-emergent adverse event, versus 21.1% in the placebo group. The most common were neutropenia (15.2% vs 5.6%), anemia (12.0% vs 4.4%), and hypokalemia (12% vs 0%). Hypokalemia was often due to diarrhea and was managed with electrolyte monitoring and potassium supplementation, Hu said. One-third of patients in the tibremciclib arm developed hypertriglyceridemia (5.4% grade 3 or higher) — a rate higher than that seen with other CDK4/6 inhibitors. Cases were managed with lipid-lowering agents such as atorvastatin. More patients on tibremciclib experienced dosing interruptions due to adverse events (54% vs 23%), and dose reductions were also more common with the combination therapy (18.5% vs 4.4%). However, only four patients (all in the tibremciclib arm) discontinued treatment due to side effects. Overall, the adverse event profile of tibremciclib lines up with that of other CDK4/6 inhibitors and comes with better PFS, Hu said, noting that "the benefit-risk balance of tibremciclib plus fulvestrant appears highly favorable." In TIFFANY, the authors note d that cases of neutropenia and leukopenia were numerically lower than in trials of abemaciclib, dalpiciclib, and palbociclib plus fulvestrant. According to Hu, tibremciclib is structurally different from other drugs in its class, with a greater selectivity for CDK4 and less inhibition of CDK6 and CDK9, which may reduce the incidence of neutropenia as well as severe diarrhea. Plus, the PFS improvement seen in TIFFANY was greater, Hu said. Pa lbociclib in PALOMA-3 showed a median PFS of 9.5 months vs 4.6 months for fulvestrant alone (HR, 0.46); abemaciclib in MONARCH led to a PFS of 11.5 months vs 5.6 months (HR, 0.38, a Chinese population); and dalpiciclib in DAWNA-1 achieved 16.6 months vs 7.2 months (HR, 0.50, also in Chinese patients). While these are cross-trial comparisons, it's still unclear exactly how tibremciclib stacks up against other drugs in its class (including its impact on overall survival). The authors also caution that, because the trial exclusively enrolled Chinese patients without prior CDK4/6 inhibitor exposure, the findings may not be generalizable to broader populations, particularly in regions like North America and Europe. Miller pointed to the generalizability question as well, noting that fulvestrant monotherapy is typically not the standard of care in the US and other Western countries. 'This [study] joins a long list of second-line endocrine studies that show drug activity but don't compare to standard of care and don't really tell us how to best use the drug,' Miller said.
